13F Holdings
中文EN

FTLF FITLIFE BRANDS, INC.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1374328 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY46.5%
TTM net income YoY1.9%
TTM EPS YoY1.5%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR17.1%

Margins

Gross margin36.7%
Operating margin11.0%
Net margin6.7%
FCF margin4.5%
EBITDA margin11.9%

Returns

ROE15.1%
ROA6.4%
ROIC (approx.)13.8%
Asset turnover0.96x

Leverage & solvency

Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.64x
Interest coverage3.93x

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio2.0%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$81.46M$64.47M$52.70M$28.80M$27.91M
Cost of revenue$50.01M$36.39M$31.27M$16.77M$15.41M
Gross profit$31.45M$28.08M$21.43M$12.03M$12.50M
SG&A expense$14.04M$9.97M$7.88M$6.01M$6.21M
Operating income$10.06M$13.12M$7.55M$5.70M$6.23M
Interest expense$1.86M$1.37M$1.02M$0—
Pretax income$8.23M$11.87M$7.00M$5.82M$6.71M
Income tax$1.90M$2.89M$1.71M$1.39M$1.30M
Net income$6.33M$8.98M$5.30M$4.43M$5.41M
EBITDA$10.48M$13.23M$7.64M$5.77M$6.29M
EPS (basic)0.680.980.590.971.23
EPS (diluted)0.630.910.540.891.13
Weighted avg. shares (diluted)9.98M9.90M9.81M4,9754.80M
Banking
Net interest income———$121,000$25,000
Balance sheet
Cash & equivalents$1.65M$4.47M$1.14M$13.28M$9.90M
Receivables$8.77M$1.63M$2.05M$705,000$945,000
Inventory$21.32M$11.07M$9.09M$9.11M$6.52M
Current assets$33.07M$18.14M$14.69M$23.20M$17.68M
PP&E, net$128,000$75,000$137,000$46,000$70,000
Goodwill$19.39M$13.02M$13.29M$358,000$358,000
Intangibles$51.44M$26.23M$26.31M$150,000$192,000
Total assets$106.32M$58.53M$55.35M$25.71M$21.51M
Current liabilities$21.61M$11.31M$10.34M$4.27M$4.06M
Short-term debt—$4.50M—$0—
Long-term debt—$8.55M$15.51M$0—
Total debt—$13.05M$15.51M$0—
Total liabilities$62.68M$22.41M$28.31M$4.32M$4.16M
Shareholders' equity$43.64M$36.13M$27.04M$21.39M$17.35M
Net debt—$8.58M$14.37M-$13.28M—
Shares outstanding9.39M9.21M9.20M4.51M4.55M
Cash flow statement
Operating cash flow$7.44M$9.61M$4.22M$4.13M$4.48M
Capital expenditure$42,000$10,000$106,000$0—
Free cash flow$7.40M$9.60M$4.11M$4.13M—
Investing cash flow-$42.54M-$10,000-$35.99M$0-$529,000
Financing cash flow$32.09M-$6.98M$20.30M-$750,000-$390,000
Depreciation & amortization$420,000$108,000$94,000$66,000$59,000
Stock-based compensation———$76,000$100,000
Share buybacks——$0$779,000$444,000

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.